AR082291A1 - Depot farmaceutico para 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridina-3-carbonitrilo - Google Patents

Depot farmaceutico para 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridina-3-carbonitrilo

Info

Publication number
AR082291A1
AR082291A1 ARP110102611A ARP110102611A AR082291A1 AR 082291 A1 AR082291 A1 AR 082291A1 AR P110102611 A ARP110102611 A AR P110102611A AR P110102611 A ARP110102611 A AR P110102611A AR 082291 A1 AR082291 A1 AR 082291A1
Authority
AR
Argentina
Prior art keywords
amino
fluoro
polymer
poly
pharmaceutical depot
Prior art date
Application number
ARP110102611A
Other languages
English (en)
Inventor
Armelle Marie Janin
Philip Alexander Laudine-Macfaul
Rachel Marie Pugh
Ian Alun Nash
Emily Jane Fuller
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR082291A1 publication Critical patent/AR082291A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un depot farmacéutico que comprende (i) 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridina-3-carbonitrilo, o una sal del mismo farmacéuticamente aceptable, como agente farmacéutico (PA) y (ii) un polímero que se degrada para crear un microentorno ácido, donde el PA se libera del polímero al degradarse el mismo.Reivindicación 2: El depot farmacéutico de acuerdo con la reivindicación 1, caracterizado porque el polímero se selecciona entre un poliéster de un hidroxiácido graso y derivados de los mismos, un polímero de un a-cianoacrilato de alquilo, un poli(oxalato de alquileno), un poli orto éster, un policarbonato, un poli orto-carbonato, un poli-aminoácido, un éster de ácido hialurónico, y mezclas de los mismos. Reivindicación 15: El depot farmacéutico de acuerdo con cualquiera de reivindicaciones 1 a 14, caracterizado porque es para la prevención o el tratamiento de la osteoartritis.
ARP110102611A 2010-07-19 2011-07-19 Depot farmaceutico para 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridina-3-carbonitrilo AR082291A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36540710P 2010-07-19 2010-07-19

Publications (1)

Publication Number Publication Date
AR082291A1 true AR082291A1 (es) 2012-11-28

Family

ID=44511084

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102611A AR082291A1 (es) 2010-07-19 2011-07-19 Depot farmaceutico para 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridina-3-carbonitrilo

Country Status (19)

Country Link
US (2) US20120022110A1 (es)
EP (1) EP2595608A2 (es)
JP (1) JP2013535443A (es)
KR (1) KR20130137592A (es)
CN (1) CN103108627A (es)
AR (1) AR082291A1 (es)
AU (1) AU2011281323A1 (es)
BR (1) BR112013001489A2 (es)
CA (1) CA2804725A1 (es)
CL (1) CL2013000174A1 (es)
CO (1) CO6670578A2 (es)
EC (1) ECSP13012447A (es)
MX (1) MX2013000774A (es)
RU (1) RU2013104639A (es)
SG (1) SG186929A1 (es)
TW (1) TW201208685A (es)
UY (1) UY33517A (es)
WO (1) WO2012010883A2 (es)
ZA (1) ZA201301246B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108871607B (zh) 2018-08-13 2020-01-03 太原理工大学 一种面向分布式光纤拉曼传感器的高精度温度解调方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6217911B1 (en) 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
KR100367144B1 (ko) * 1997-07-02 2003-01-14 유로-셀티크 소시에떼 아노뉨 관절과 체강(ｂｏｄｙ ｓｐａｃｅ)내에서 연장된 마취
CN100528224C (zh) * 2004-09-27 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 含干扰素α-1b的注射用缓释微球及其制备方法
CN1631362A (zh) * 2004-11-26 2005-06-29 中国科学院上海药物研究所 一种抗肿瘤控释组合物及其制备方法
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
CN1308034C (zh) * 2004-12-27 2007-04-04 中山大学 一种干扰素聚乳酸－羟乙酸共聚物plga微球的制备方法
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
CN100457187C (zh) * 2006-11-10 2009-02-04 中国人民解放军第二军医大学 Vegf缓释注射微球支架及其制备方法和用途
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249

Also Published As

Publication number Publication date
JP2013535443A (ja) 2013-09-12
KR20130137592A (ko) 2013-12-17
SG186929A1 (en) 2013-02-28
EP2595608A2 (en) 2013-05-29
WO2012010883A3 (en) 2012-09-07
MX2013000774A (es) 2013-03-22
CO6670578A2 (es) 2013-05-15
RU2013104639A (ru) 2014-08-27
AU2011281323A1 (en) 2013-02-28
TW201208685A (en) 2012-03-01
CA2804725A1 (en) 2012-01-26
ZA201301246B (en) 2014-05-28
US20120022110A1 (en) 2012-01-26
CL2013000174A1 (es) 2013-03-08
BR112013001489A2 (pt) 2016-05-31
WO2012010883A2 (en) 2012-01-26
CN103108627A (zh) 2013-05-15
ECSP13012447A (es) 2013-03-28
UY33517A (es) 2012-02-29
US20140045895A1 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
BR112016012794A2 (pt) Combinação terapêutica de um inibidor de pi3k e um inibidor de btk
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
AR083395A1 (es) Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
MX2019011333A (es) Composiciones y metodos para el uso de esteres de forbol para el tratamiento de accidentes cerebrovasculares.
AR067824A1 (es) Compuestos de acido boronico y ester boronico inhibidores de la proteasoma, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento del cancer.
PH12014502849A1 (en) Methods of reducing the risk of a cardiovascular event in a subject on a statin therapy
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
CL2009000625A1 (es) Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo.
ECSP11011403A (es) Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
ECSP099376A (es) Inhibidores de la actividad de la akt
CL2012001080A1 (es) Dispersión sólida de rifaximina y un portador farmacéuticamente aceptable; composición farmacéutica; uso en el tratarmiento y/o prevención de una infecciíon microbiana que comprende la administración de la dipersión sólida.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
MY161930A (en) Antipsychotic injectable depot composition
CR11065A (es) Administracion semanal de inhibidores de peptidasa de dipeptidilo
GT201300172A (es) Inhibidores de serina proteasa de hepatitis c a base de macrocicilicos de fenantridina
ES2720954T3 (es) Formulaciones estabilizadas de estatina
FI3970707T3 (fi) Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon
AR085132A1 (es) Composiciones farmaceuticas para el tratamiento de glioma maligno
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
BR112012015437A2 (pt) composição tópica substancialmente anidra de armazenamento estável
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure